Warning (2): Creating default object from empty value [APP/Controller/WebController.php, line 274]
UTHSCSA Find-A-Study
Photo of Clinical Research Volunteers
Office of the Vice President for Research
FindAStudy :: Human Studies @ UTHSCSA
312  Studies 178  Researchers 30  Categories
× Server Error: Please contact a VPR IT team member for assistance.
× Result: 97 studies found using "cancer"
No studies found - try again with different search terms.
Choose a Category Below to Show a List of Study Titles
  •   Aging and Geriatric

    •   Characterizing Frailty and the Plasma Glycopreome in Older Veterans
      Protocol No.
      HSC20080234H
      Official Title
      Characterizing Frailty and the Plasma Glycopreome in Older Veterans
      Description
      The purpose of this study is to study protein changes and other biomarkers in the blood that occur with aging. Over the past decade, advances in biomedical science and technology have led to the development of state-of-the-art laboratory techniques for studying proteins in a blood sample. This is called comparative proteomics, where researchers compare hundreds, even thousands, of proteins in the blood for people with different diseases. For example, it has been used to identify cancer in people without having to have a biopsy, which is a needle that is used to get tissue from the inside of the body. Until now, comparative proteomics has only been used in animals to study changes in proteins with aging. We believe that by applying these methods in humans, we can better understand what happens inside the body as a person ages. We believe this information (how the proteins from a blood sample change with age) can help us to find ways in which we can help people age successfully and remain independent into late life.
      Contact
      210-617-5197
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Cancers and Other Neoplasms

    •   Brain & Nervous System

      •   A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy...
        Protocol No.
        HSC20130212H
        Official Title
        A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination with Bevacizumab for Glioblastoma Following Bevacizumab Failure (CTRC# 12-0105)
        Description
        Researchers want to find out if an investigational drug called TH-302 can help treat patients with brain tumors (glioblastoma) when it is combined with another drug called bevacizumab (anti-angiogenic agent). The purpose of this study is to determine how effective the drug combination is in treating cancer as well as gathering information on how safe it is to give this drug (TH-302 plus bevacizumab) combination to patients.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase II, Open-Label, Multi-Center Study of ANG1005 in Her2+ Breast Cancer...
        Protocol No.
        HSC20140206H
        Official Title
        A Phase II, Open-Label, Multi-Center Study of ANG1005 in Her2+ Breast Cancer Patients with Progressive/Recurrent Brain Metastases
        Description
        To determine the iORR as evaluated by IRF
        Contact
        (210) 450-5964
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A221101 A Phase III Randomized, Double-Blind Placebo Controlled Study of...
        Protocol No.
        HSC20140301H
        Official Title
        A221101 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
        Description
        To determine preliminary efficacy measured by patient reported fatigue (BFI) at 8 weeks of two doses (150mg and 250mg) of armodafinil in treating moderate fatigue compared to placebo in patients with high grade glioma
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   ANBL0032, Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in...
        Protocol No.
        HSC20090466H
        Official Title
        ANBL0032, Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
        Description
        This research study of a continued treatment for high risk neuroblastoma for patients that have undergone treatment for high risk neuroblastoma.
        Contact
        210-567-7482
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   ANG1005 as Treatment for Recurrent High-Grade Glioma
        Protocol No.
        HSC20130484H
        Official Title
        A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients with Recurrent High-Grade Glioma (CTRC# 13-0050)
        Description
        The primary objective is to determine the overall response rate and progression-free status of glioma patients treated with ANG1005. The study will enroll approximately 83 patients from one or more cancer centers in the US. In addition to other conditions for enrollment, eligible patients have recurrent or progressive glioma, are neurologically stable, and have adequate lab results.   Patients who have a history of 3 or more relapses, prior treatment with taxol or docetaxel, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-5816
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Combination Chemotherapy with or without Radiation Therapy in Treating...
        Protocol No.
        HSC20130312H
        Official Title
        RTOG 1114 Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
        Description
        This Phase III study is designed to compares how well giving rituximab and combination chemotherapy works with or without radiation therapy in treating patients with primary central nervous system non-Hodgkin’s lymphoma. The study will enroll approximately 89 patients from many cancer centers in the US. In addition to other conditions for enrollment, eligible patients have B-cell NHL involving the brain. Patients who have a history of significant cardiac events, active infections, chronic obstructive pulmonary disease, compromised immune system, or inadequate live function or other severe medical conditions may not be eligible to enroll.
        Contact
        210-450-5924
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   RTOG 0925 Natural History of Postoperative Cognitive Function, Quality of...
        Protocol No.
        HSC20140276H
        Official Title
        RTOG 0925 Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients With Supratentorial Low-Risk Grade II Glioma
        Description
        To determine if there is difference in the average changes of neurocognitive function scores from baseline to the time of radiologic tumor progression.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   RTOG 1119 Phase II Randomized Study Of Whole Brain Radiotherapy In...
        Protocol No.
        HSC20140321H
        Official Title
        RTOG 1119 Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study
        Description
        To determine if there is a signal for an increase in complete response (CR) rate in the brain at 12 weeks post WBRT (Whole Brain Radiotherapy) as determined by MRI scan of the brain, with the addition of lapatinib to WBRT compared to WBRT alone.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Study of DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer
        Protocol No.
        HSC20120273H
        Official Title
        A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (CTRC# 12-20)
        Description
        The primary purpose of the study is to determine the usefullness of new therapy called DCVax®-L in patients who have newly diagnosed GBM and surgery is planned. Patients must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive the standard of care, including radiation and temozolomide (Temodar) therapy and two out of three will additionally receive DCVax-L, with the remaining one third receiving a placebo. Patients randomized to the placebo arm will have the option to receive DCVax-L in a crossover arm upon documented disease progression. The study will enroll approximately 300 patients from at least 50 cancer centers in the US and UK. In addition to other conditions for enrollment, eligible patients have newly diagnosed, unilateral GBM (grade IV). Participants must have sufficient tumor lysate protein that was generated from the surgically obtained tumor material. Patients must also have sufficient DCVax-L product available after manufacturing.
        Contact
        (210) 450-5816
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   TH-302 as Treatment for Recurrent High Grade Astrocytoma following Treatment...
        Protocol No.
        HSC20110360H
        Official Title
        A Phase 2, Investigator Initiated Study to Determine the Safety, Efficacy and CNS Penetration of TH-302 in Recurrent High Grade Astrocytoma following Bevacizumab (CTRC#11-24)
        Description
        This Phase II study evaluates the usefulness of TH-302 in treating astrocytoma. The study objectives are to identify the side effects of TH-302 by itself and of TH-302 plus bevacizumab; and to determine the best dose of TH-302 to use when it is combined with bevacizumab. The study will enroll approximately 28 patients from the CTRC in San Antonio, TX. In addition to other conditions for enrollment, eligible patients must have a diagnosis of high grade astrocytoma that has become worse after prior treatment with radiation and temozolomide, but are otherwise in good health. Adult patients who have a history of acute intracranial or intratumoral bleeding, a ruptured or unhealed wound, high blood pressure, infection, recent cardiac problems, or a lung disease or disorder that causes low oxygen levels may not be eligible to enroll.
        Contact
        (210) 450-5964
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   VB-111 as Treatment for Recurrent Glioblastoma
        Protocol No.
        HSC20110075H
        Official Title
        A Phase I/II Single-Arm Open-Label Multicenter Study of VB-111 in Patients with Recurrent Glioblastoma Multiforme
        Description
        This is a Phase I/II open label, dose escalating, multi-center study. The primary objective is to identify the side effects and effectiveness of VB-111. The study will enroll approximately 35 patients from 3 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have diagnosis of glioblastoma multiforme or gliosarcoma that has become worse after treatment with radiation and temozolomide, but are otherwise in good health. Adult patients who have a history of prior treatment with bevacizumab, aflibercept or similar drug may not be eligible to enroll. In addition, a recent cardiac event, active vascular disease, or vascular retinopathy may not be allowed for enrollment.
        Contact
        (210) 450-5964
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Breast - Female

      •   Adipose Stromal Cells (ASCs) and Breast Cancer. Subtitle:" Adipose Aromatase...
        Protocol No.
        HSC20080058H
        Official Title
        Adipose Stromal Cells (ASCs) and Breast Cancer. Subtitle:" Adipose Aromatase Expression and Breast Cancer"
        Description
        A research study evaluating risk factors associated with breast cancer. Fat from tissue removed during surgery may have great potential to benefit our understanding of how to better prevent breast cancer. The researchers hope to learn what role obesity and fat tissue play in breast cancer.
        Contact
        210-562-4159
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Chemotherapy With or Without Trastuzumab after Surgery as Treatment for...
        Protocol No.
        HSC20120223H
        Official Title
        B47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer (CTRC# 12-28)
        Description
        The purpose of this study is to determine if chemotherapy after surgery works better with or without trastuzumab as treatment for women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.  The primary objective is to determine which treatment works better based on how long it takes for breast cancer to come back, if ever. The study will enroll 3,260 participants from many cancer centers in the US. After completing study treatment, patients are followed up every 6 months for 5 years and then every 12 months for 5 years. In addition to other conditions for enrollment, a woman with no evidence of cancer after surgery to remove the breast cancer, and the surgery was within the past 84 days.  Radiation therapy must be completed at the time of study enrollment. Eligible patients have at least 1 positive lymph node but no evidence of cancer that has spread beyond the breast or lymph nodes.  Eligible patients cannot have a history of heart disease, uncontrolled diabetes, active hepatitis B or C, or shortness of breath due to an existing lung problem. Patients with inflammatory breast cancer are not eligible.
        Contact
        210-450-5715
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Genetics of Lymphedema after Breast Cancer Treatment
        Protocol No.
        HSC20080150H
        Official Title
        Genetics of Lymphedema after Breast Cancer Treatment
        Description
        A research study of arm swelling (lymphedema) after breast cancer treatment. The researchers hope to learn about the potential causes of arm swelling after breast cancer treatment.
        Contact
        210-562-9123
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase III Study of fulvestrant plus BKM120 versus fulvestrant plus placebo...
        Protocol No.
        HSC20120295H
        Official Title
        NULL
        Description
        This Phase III multi-center (global), randomized, double-blind, placebo controlled study is designed to determine the efficacy and safety of treatment with fulvestrant plus BKM120 versus fulvestrant plus placebo in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer. The primary objective is to determine if BKM120 improves the ability of fulvestrant to prevent the cancer from becoming worse. The study will enroll approximately 842 patients from more than 250 cancer centers in the US, Canada, Europe, Australia, South America, and Asia. In addition to other conditions for enrollment, eligible patients have HER2-negative, hormone receptor positive, locally advanced or metastatic breast cancer after treatment with hormonal therapy and are otherwise in good health. Patients who have a history of previous treatment with fulvestrant (Faslodex®), brain metastases, certain heart disease conditions may not be eligible to enroll.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Quality of life following breast conservation therapy vs mastectomy with...
        Protocol No.
        HSC20130002H
        Official Title
        Quality of life following breast conservation therapy versus mastectomy with reconstruction in women with primary breast cancer (CTRC#12-0091)
        Description
        A research study of breast cancer. Breast cancer is currently treated with surgery to remove the tumor. Some patients also require a combination of chemotherapy and radiation. This study is designed to identify patients at high risk for feeling that their surgery has caused their breasts to no longer be visually appealing. We are specifically interested in seeing if the involvement of a plastic surgeon can influence how breast cancer patients feel about their surgical result. If we succeed in proving this, we hope that many women in the future with breast cancer could benefit by routinely including a plastic surgeon in their care. The researchers hope to learn if a plastic surgeon should be routinely involved in the care of breast cancer patients at high risk for feeling that their surgery will result in a poor appearance of their breasts.
        Contact
        210-567-5711
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Radiation Therapy With or Without Trastuzumab as Treatment for Women with...
        Protocol No.
        HSC20100403H
        Official Title
        NSABP B-43 A Phase III Clinical trial Comparing Trastuzumab given concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2 Positive Ductal Carcinoma in Situ Resected by Lumpectomy
        Description
        The purpose of this study is to find out if taking trastuzumab with radiation therapy works any better than radiation therapy without trastuzumab when treating women with ductal breast cancer in situ who have undergone lumpectomy. Radiation therapy uses high-energy x-rays to kill tumor cells.  Trastuzumab blocks tumor growth in other ways. The primary objective is to determine which treatment works best to prevent subsequent occurrence or recurrence of breast cancer or ductal carcinoma in situ (DCIS). The study will enroll 2,000 participants from many cancer centers in the US. In addition to other conditions for enrollment, women with HER2-positive DCIS that was removed by lumpectomy within the past 120 days may be eligible. Eligible patients must not be candidates for mastectomy, cannot have a positive lymph node, and cannot have a history of heart disease. Eligible patients cannot have had prior whole or partial breast radiation therapy.
        Contact
        210-450-1795
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Rx for Better Breast Health
        Protocol No.
        HSC20140150H
        Official Title
        Rx for Better Breast Health
        Description
        We will determine the effects of anti-inflammatory cuisine on breast cancer survivor''s health, their eating habits and on certain blood markers. Culinary workshops and newsletters will be given to intervention group who will be guided and encourage to work towards study goals by patient navigators.
        Contact
        210-562-6515
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Tamoxifen, Letrozole, Anastrozole, or Exemestane With or Without...
        Protocol No.
        HSC20110363H
        Official Title
        S1007 - A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
        Description
        The purpose of this study is studying whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane works better with or without chemotherapy when treating patients with breast cancer. The results of this study will show whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective when taken with combination chemotherapy. Estrogen can cause the growth of breast cancer cells. Hormone therapy, such as tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Drugs such as anastrozole, letrozole, and exemestane may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from reproducing. The primary objective is to determine the effect of the treatment in invasive disease-free survival (DFS) of women with node-positive breast cancer treated with endocrine therapy with vs without chemotherapy. The study will enroll 9,400 participants from many cancer centers in the US. In addition to other conditions for enrollment, women with a diagnosis of invasive breast cancer, 1 to 3 positive lymph nodes, estrogen receptor  and/or progesterone receptor positive, and HER-2 negative.  Eligible patients have had surgery and completed radiotherapy, if it was recommended.
        Contact
        450-1886
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Buccal Cavity and Pharnyx

      •   Alterations in Vitamin D metabolism in newly diagnosed thyroid cancer with...
        Protocol No.
        HSC20090508H
        Official Title
        Alterations in Vitamin D metabolism in newly diagnosed thyroid cancer with changing thyroid states
        Description
        A research study of the effects of thyroid hormone on vitamin D levels. The researchers hope to learn about changes in levels of vitamin D in the blood and changes in thyroid levels as part of the treatment of thyroid cancer.
        Contact
        210-567-4902
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Dalantercept (ACE-041) as Treatment for Patients with Head and Neck
        Protocol No.
        HSC20120058H
        Official Title
        An Open-Label Phase 2 Study of Dalantercept in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CTRC# 11-68).
        Description
        This is a Phase 2 study to evaluate ACE-041 at treatment for patients with recurrent or metastatic squamous cell cancer of the head and neck that have been previously treated with a platinum containing regimen. The primary objective is to identify the response rate to treatment, plus the safety and tolerability of dalantercept. The study will enroll approximately 45 patients from up to 15 cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those whose tumors have become worse in spite of treatment and who are otherwise in good health. Eligible head and neck cancers are those that are recurrent or metastatic and of mucosal origin (oral cavity, oropharynx, hypopharynx, or larynx) but not amenable to localized therapy (surgery or radiation including re-irradiation); Not included in this study are nasopharyngeal carcinoma, paranasal sinus, salivary gland or primary skin cancers. Adult patients who have a history of cancer involving the central nervous system (brain), evidence of active infection or hepatitis B or C, uncontrolled hypertension, requiring anti-coagulation therapy, or recent cardiac events may not be eligible to enroll may not be eligible to enroll.
        Contact
        (210) 450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Novel Mechanisms of Oral Cancer Pain Associated with Patient Reported Pain
        Protocol No.
        HSC20110197H
        Official Title
        Novel Mechanisms of Oral Cancer Pain Associated with Patient Reported Pain
        Description
        The purpose of this study is to understand the types of oral cancer pain patients experience in order to develop new treatments to alleviate this pain. This study will evaluate the types of pain and how much pain oral cancer patients experience before they receive treatment of their cancer.
        Contact
        210-450-0739
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Oral Afatinib as Adjuvant Therapy for Patients with Head and Neck Cancer...
        Protocol No.
        HSC20120101H
        Official Title
        NULL
        Description
        This Phase III study compares afatinib to placebo. Enrolled patients are assigned randomly to either afatinib or placebo at a rate of 2 to 1. A double-blind study means that neither the doctor nor the patient will know which one is being used. The primary objective is to determine whether or not the addition of afatinib works better than nothing as a treatment for preventing head and neck cancer from recurring after having been treated with chemotherapy and radiation.  The study will enroll 669 patients from many cancer centers in the US, Canada, and many other countries. In addition to other conditions for enrollment, eligible patients are those whose head and neck tumors began in the oral cavity, oropharynx, hypopharynx, or larynx) and have been treated. Not included in this study are cancers of the nasopharynx, sinuses, or salivary glands. Adult patients who have a history of uncontrolled hypertension or significant cardiovascular abnormalities, active infection including hepatitis B or C, or significant gastrointestinal disorders may not be eligible to enroll.
        Contact
        (210) 450-5816
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase I Dose Escalating Study of Cetuximab plus EGFR AS DNA for Patients...
        Protocol No.
        HSC20120131H
        Official Title
        Safety and Efficacy Evaluation of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Elderly or Cisplatin-Ineligible Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (CTRC# 11-47)
        Description
        The purpose of this study is to determine the if adding EGFS AS DNA to standard cetuximab and radiation when treating people with head and neck cancer is a safe and effective treatment. The primary objective is to evaluate the safety of combining intratumoral EGFS AS DNA with standard cetuximab and radiation when treating people with head and neck cancer that cannot be removed surgically. The study will enroll between 11 and 42 participants from the Cancer Therapy and Research Center in San Antonio. In addition to other conditions for enrollment, eligible patients have SCCHN tumors that are suitable for intratumoral injections of EGFR AS and are candidates for loco-regional radiation treatments. EGFR AS is administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as determined clinically.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Texas Cancer Diagnostics Pipeline: Oral Cancer Subproject
        Protocol No.
        HSC20110108H
        Official Title
        Texas Cancer Diagnostics Pipeline: Oral Cancer Subproject
        Description
        A research study to develop and test an investigational microchip sensor system for the diagnosis, testing and monitoring of potentially malignant and malignant lesions of the mouth. We hope to learn if an optical biosensor can accurately detect differences from multiple sites in the mouth and/or between abnormal and normal tissue using surface cells removed from the mouth with a small brush.
        Contact
        210-450-0739
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Cancer Site Not Specified

      •   Flow Cytometric Detection of In Vivo Red Cell Bound Immunoglobulin in...
        Protocol No.
        HSC20130347H
        Official Title
        Flow Cytometric Detection of In Vivo Red Cell Bound Immunoglobulin in Sickle Cell Disease: Clinical Relevance in Alloimmunization
        Description
        The purpose of the study is to detect via flow cytometry low levels of immunoglobulins IgA, IgG, and IgM on red blood cells from patients with sickle cell disease and other hematologic diagnoses and to correlate these results with clinical status and outcome.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Survey of human nasal microbiota
        Protocol No.
        HSC20130374H
        Official Title
        Survey of human nasal microbiota
        Description
        The purpose of this study is to collect specimens of bacteria and identify them; to learn which kinds of non-disease causing bacteria are normally present in the nose. In future studies,researchers hope to use the bacteria that do not cause disease (good bacteria) to get rid of the bacteria that cause disease (bad bacteria.) Researchers are also trying to identify persons who have the bad bacteria in the nose, to offer participation in these future studies.
        Contact
        210-548-0346
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Colon

      •   FOLFOX6 with or without PledOx as treatment for metastatic colorectal cancer
        Protocol No.
        HSC20120332H
        Official Title
        A double blinded randomized three armed phase II trial of PledOx® in two different doses incombination with FOLFOX6 compared to placebo + FOLFOX6 in patients with advanced metastatic colorectal (stage IV) cancer (PLIANT study) (CTRC# 12-0048)
        Description
        This is a Phase 2 designed to determine whether pre-treatment with PledOx makes a difference compared to a placebo in lowering the frequency and severity of side effects from FOLFOX6 therapy without interfering with the anti-tumor efficacy when treating metastatic colorectal cancer. The primary objective is to identify the side effects of PledOx. The study will enroll approximately 138 patients from many cancer centers in the US and Europe. In addition to other conditions for enrollment, eligible patients have metastatic colorectal cancer that has not been treated with chemotherapy and are otherwise in good health. Adult patients who have a history of unresolved bowel obstruction or uncontrolled Crohn''s disease, stroke, cerebrovascular accident, chronic diarrhea, active infection, peripheral neuropathy, high manganese exposure, or neurodegenerative disease may not be eligible to enroll.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Kidney

      •   Everolimus vs Nothing as Treatment for Kidney Cancer After Kidney Surgery
        Protocol No.
        HSC20110362H
        Official Title
        S0931 - EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
        Description
        The purpose of this study is to see how well everolimus works as a prevention treatment for kidney cancer patients who have undergone surgery to remove all or part of a kidney. The primary objective is to determine if everolimus works better than taking nothing for preventing kidney cancer from coming back after surgery. The study will enroll 1170 participants from many cancer centers in the US. In addition to other conditions for enrollment, patients have a diagnosis of renal cell or clear cell kidney cancer but no evidence of cancer in other parts of the body.  Eligible patients have recovered from the kidney surgery and have not received any other treatment for their cancer.  Eligible patients are able to take oral medications and do not have any digestive problem that would affect how well a drug is digested.  Patients are not eligible if they have uncontrolled diabetes, impaired liver function, or impaired breathing function.
        Contact
        210-450-1785
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Study of BMS-936558 vs. everolimus in pre-treated advanced or metastatic...
        Protocol No.
        HSC20130129H
        Official Title
        A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy (CTRC# 12-0066)
        Description
        The purpose of the main study is to compare the effectiveness (how well the drug works), safety, and tolerability of an investigational drug, BMS-936558 against the approved drug, everolimus, in subjects with advanced or metastatic renal cell carcinoma. BMS-936558 is an antibody (a type of human protein) that is being tested to see if it will allow the body''s immune system to work against tumor cells.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Liver

      •   ACRIN 6690: A Prospective, Multicenter Comparison of Multiphase Contrast...
        Protocol No.
        HSC20110093H
        Official Title
        ACRIN 6690: A Prospective, Multicenter Comparison of Multiphase Contrast Enhances CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
        Description
        The purpose of this study is to determine and compare how accurate CT and MRI are in diagnosing liver cancer. For people with liver cancer, and other liver disease, the most effective way to treat their disease may be a liver transplant. This study is testing two non-invasive ways of looking inside the body at the liver. The research doctors hope to learn whether images from a CT scan or from an MRI scan provide the best information about liver condition. To discover which is better, the images from both the CT and MRI scans will be compared to the actual liver after it is removed during transplant surgery and examined. With improved imaging methods, the study doctors believe they can better manage the liver transplant waiting list.
        Contact
        210-567-9201
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   G-202 as second-line therapy following sorafenib in hepatocellular carcinoma
        Protocol No.
        HSC20130231H
        Official Title
        A Phase II, Multicenter, Single-Arm Study of G-202 as Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma (CTRC# 12-0098)
        Description
        This Phase II study evaluates the anti-tumor activity and safety of G-202 as treatment for patients with hepatocellular carcinoma whose disease has progressed after taking sorafenib. The primary objective is to determine the duration of time from the first administration of G-202 to the time of radiologic progression. The study will enroll approximately 29 patients from up to 10 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have hepatocellular carcinoma (HCC) that has become worse on sorafenib therapy but who still have adequate liver and kidney function, and are otherwise in good health. Patients who have a history of recent trans-arterial chemoembolization or major surgery, biliary infection, severe ascites, viral hepatitis, cardiac disease or hypertension, or active infection may not be eligible to enroll.
        Contact
        (210) 450-5816
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Genetics & Biology of Liver Tumorigenesis in Children
        Protocol No.
        HSC20100482H
        Official Title
        Genetics & Biology of Liver Tumorigenesis in Children
        Description
        The overall goals of this Multi-Investigator Research Proposal is to further the understanding of the development and identify prognostic characteristics of liver tumors in children, particularly hepatoblastoma and its variants through a combined genomic and molecular pathology approach.
        Contact
        210-562-9123
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the...
        Protocol No.
        HSC20120330H
        Official Title
        Phase 3 Prospective, Randomized, Blinded and Controlled Investigation of Hepasphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
        Description
        The purpose of this study is to evaluate overall survival in patients treated with HepaSphere/Quadrasphere compared to conventional transarterial chemoembolization with particle PVA. Eligible adult patients have a diagnosis of hepatocellular cancer and are not currently or previously treated with chemo- or radiation therapy or sorafenib. Estimated Enrollment: 520 from multiple cancer centers in the US and Europe.
        Contact
        210-567-5604
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase I Dose Escalating Study of TKI258 for Patients with Advanced or...
        Protocol No.
        HSC20120207H
        Official Title
        A Multi-Center, Open-Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients with Normal and Impaired Hepatic Function (CTRC# 12-15)
        Description
        The purpose of this study is to determine the best dose of TKI258 to use when treating people with a liver that does not work well and cancer that has spread to other areas in the body and/or cannot be removed surgically. The primary objective is to compare the effects of mild or moderate liver dysfunction to normal liver function in the way that TK1258 (dovitinib) is metabolized (or broken down and passed from the body) in patients with advanced solid tumors. The study will enroll approximately 18 to 48 participants from 3 cancer centers in the US, 4 cancer centers in Europe, and 1 cancer center in China. In addition to other conditions for enrollment, eligible patients are those whose tumors have become worse in spite of treatment and who are otherwise in good health.  Patients may not be eligible for treatment on this study if they have a history of cancer involving the central nervous system (brain), blood clotting problems, difficulty swallowing or digesting oral medications, or had a liver transplant. Patients with certain heart conditions, uncontrolled high blood pressure, uncontrolled diabetes, an active infection, or taking blood-thinning medications may not be eligible for treatment.
        Contact
        (210) 450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   RP120462 Environmental Determinants of Hepatocellular Carcinoma in South Texas
        Protocol No.
        HSC20120181H
        Official Title
        RP120462 Environmental Determinants of Hepatocellular Carcinoma in South Texas
        Description
        A research study of Hepatocellular Carcinoma (HCC). This study needs to be done because of the trend of increasing HCC both nationally, and particularly in our predominantly Hispanic South Texas population. We also observed a number of liver cancer cases near the former Kelly Air Force Base in San Antonio, and higher than expected levels of aflatoxin in nearby residents. The researchers hope to learn what risk factors are important for development of HCC in South Texas. Identification of these risk factors could lead to a significant decrease in the burden of this disease in South Texas and other populations.
        Contact
        210-567-0846
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Lung

      •   A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG Injection in...
        Protocol No.
        HSC20110121H
        Official Title
        A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG Injection in Combination with Bevacizumab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (IDD
        Description
        The researchers hope to learn more about the anti-tumor activity and safety of Imprime PGG® when used in combination with bevacizumab, paclitaxel and carboplatin therapy for lung cancer. This study involves the use of an investigational drug called Imprime PGG®. "Investigational" means that the drug has not yet been approved by the U.S. Food & Drug Administration (FDA) for treating lung cancer.
        Contact
        210-450-5863
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Carboplatin & Paclitaxel With or Without Bevacizumab and/or Cetuximab in...
        Protocol No.
        HSC20120217H
        Official Title
        S0819 - A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (CTRC# 12-24)
        Description
        The purpose of this study is to compare how well treatment with carboplatin and paclitaxel with or without bevacizumab works with or without cetuximab as therapy for patients with stage IV or recurrent non-small cell lung cancer. The primary objective is to compare overall survival (up to 3 years) based on the different treatment used. The study will enroll 1,700 participants from many cancer centers in the US. In addition to other conditions for enrollment, eligible patients have newly diagnosed stage IV lung cancer or their lung cancer has recurred after prior surgery and/or radiation therapy. Study participants have not been previously treated with chemotherapy or bevacizumab.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Hypofractionated Image-Guided Radiation Therapy (IGRT) for patients with...
        Protocol No.
        HSC20120093H
        Official Title
        Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status
        Description
        The study is designed to determine whether an accelerated course of hypofractionated radiation therapy with daily image guidance and motion assessment/control will allow more effective treatment of poor performance status patients with stage II-III non-small cell lung cancer (NSCLC), who would benefit from local therapy compared to standard radiation therapy (60 Gy in 2 Gy per fraction). The primary objective is to compare one type of radiation therapy with another type in order to determine if one is better than the other.    The study will enroll approximately 226 patients from 5 cancer centers in Texas. In addition to other conditions for enrollment, eligible patients have state II or III NSCLC and are otherwise in good health. Patients who have a history of radiotherapy to the area that overlaps the area to be treated may not be eligible to enroll.
        Contact
        210-450-5924
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase 2 study of VS-6063 as Treatment for Non-Small Cell Lung Cancer with a...
        Protocol No.
        HSC20130445H
        Official Title
        Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients with KRAS Mutant Non-Small Cell Lung Cancer (CTRC# 13-0035)
        Description
        This Phase 2 study is designed to evaluate VS-6063 (defactinib) in patients with non-small cell lung cancer that has a specific genetic (KRAS) mutation.   The primary objective is to determine if treatment with VS-6063 (defactinib) improves the time to disease progression. The study will enroll approximately 150 patients from at least 5 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have non-small cell lung cancer that has a specific genetic (KRAS) mutation. Patients who have a history of untreated brain metastasis, known impairment of gastrointestinal function that would affect drug absorption, evidence of cardiac risk, or uncontrolled hypertension or other severe medical conditions may not be eligible to enroll.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   S1206, A Dose Finding Study Followed by Phase II Randomized,...
        Protocol No.
        HSC20130133H
        Official Title
        S1206, A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (CTRC# 12-0094)
        Description
        The purpose of this study is to find out what effects, good and/or bad, a new combination of treatment has on cancer. This study will be conducted in two parts. Participants will take part in either Part I or Part II, but not both. In Part I of the study the researchers are hoping to decide what the best dose of the investigational drug veliparib is to be given to participants. Part II will begin after the work with Part I has ended. In Part II researchers will look to see if the combination of veliparib plus chemotherapy will improve lifespans without the disease returning in participants with unresectable Stage III NSCLC.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Multiple Myeloma

      •   A Phase 1/2 Study of Weekly Carfilzomib in Combination with Dexamethasone...
        Protocol No.
        HSC20130151H
        Official Title
        A Phase 1/2 Study of Weekly Carfilzomib in Combination with Dexamethasone for Relapased Multiple Myeloma (CTRC# 12-0100)
        Description
        Phase 1: Determine the maximum tolerated dose (MTD) for patients with progressive multiple myeloma treated with weekly carfilzomib and dexamethasone. Phase 2: Estimate the overall response rate (ORR, defined as the proportion of patients who achieve a confirmed PR or better) for patients with progressive multiple myeloma treated with weekly carfilzomib and dexamethasone.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   BT062 in Combination with Lenalidomide and Dexamethasone as Treatment for...
        Protocol No.
        HSC20120168H
        Official Title
        A Phase I/IIa Multi-Dose Escalation Study of BT062 in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Relapsed/Refractory Multiple Myeloma (CTRC# 12-09)
        Description
        This is a two-part study. The Phase I part of the study is a dose-escalation study designed to evaluate the safety and tolerability of BT026 when used in combination with lenalidomide and dexamethasone.  The Phase II part of the study is designed to evaluate the effectiveness of the 3-drug combination when treating patients with relapsed or refractory multiple myeloma. The study will enroll up to 18 patients in Part 1 and up to 31 patients in Part 2 from 4 cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those whose disease has become worse in spite of treatment and who are otherwise in good health. Eligible patients are able to swallow capsules and comply with taking oral medications. Adult patients who have a history of blood clots, active infection including hepatitis, uncontrolled hypertension, heart attack or other cardiac complications may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Multiple sites

      •   A Phase 1 Study of CBL0137 in Patients with Metastatic or Unresectable...
        Protocol No.
        HSC20130328H
        Official Title
        A Phase 1 Trial of CBL0137 In patients With Metastatic or Unresectable Advanced Solid Neoplasms or Refractory Lymphomas (CTRC# 13-0031)
        Description
        This Phase 1 study is designed to determine the best dose of CBL0137 to use when treating patients with metastatic or unresectable advanced solid tumors or lymphoma. The study will enroll up to 48 patients from at least 2 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have cancer that has not improved or has come back after prior treatment and are otherwise in good health. Patients who have a history of active infection, cancer involving the central nervous system, a particular EKG abnormality or other serious medical conditions may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase 1 Study to Evaluate MEDI4736 at Treatment for Advanced Malignant...
        Protocol No.
        HSC20120299H
        Official Title
        A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors (CTRC#12-0061)
        Description
        This Phase I study is designed to evaluate MEDI4736 in advanced cancer patients. The primary objective is to determine the best dose of MEDI4736 to use when treating patients with metastatic or unresectable advanced solid tumors. The study will enroll approximately 90 patients from at least 5 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced malignant melanoma, renal cell carcinoma, non-small cell lung cancer, or colorectal cancer that has not responded to standard therapy and for which no standard therapy exists. Patients who have a history of treatment with an anti-PD-1 agent/antibody, tuberculosis, hepatitis A, B, or C infection, symptomatic or untreated central nervous system disease or other severe medical conditions may not be eligible to enroll.  
        Contact
        (210) 450-1912
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase 1, Dose Escalation Study of MLN7243 in Adult Patients with Advanced...
        Protocol No.
        HSC20140098H
        Official Title
        A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors
        Description
        This Phase 1 is designed to evaluate safety, tolerability, and antitumor effectiveness of MLN7243 in adult patients with advanced cancer. The primary objective is to identify the best dose of MLN7243 to use in treating cancer. The study will enroll approximately 119 patients from at least 2 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced cancer for which no standard therapy is available and otherwise in good health. Patients who have a history of cardiac impairment, brain metastases, active infection, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase I, Multi-Center, Open-Label, Drug-Drug Interaction Study to Assess...
        Protocol No.
        HSC20120271H
        Official Title
        A Phase I, Multi-Center, Open-Label, Drug-Drug Interaction Study to Assess the Effect of the CYP1A2 Inhibitor, Fluvoxamine, on Dovitinib (TKI258) Pharmacokinetics in Patients with Advanced Solid Tumors (CTRC# 12-0049)
        Description
        A research study to find out if the drug dovitinib is safe and has beneficial effects in people who have advanced solid tumors.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and...
        Protocol No.
        HSC20080005H
        Official Title
        A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients with Advanced Metastatic Cancer (IDD #07-56)
        Description
        A research study of a new investigational (experimental) drug called VB-111 to treat advanced metastatic cancer (cancer that has spread to other parts of the body) and we want to learn if VB-111 will have a good effect on the cancer, such as keeping the cancer cells from dividing and growing. "Investigational" means that VB-111 has not been approved by the Food and Drug Administration (FDA) for commercial use, sale or marketing.
        Contact
        210-450-5863
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Rollover Study to Provide Continued Treatment with GSK2118436 to Subjects...
        Protocol No.
        HSC20130061H
        Official Title
        A Rollover Study to Provide Continued Treatment with GSK2118436 to Subjects with BRAF Mutation-Positive Tumors (CTRC# 12-0092)
        Description
        A research study of Dabrafenib, which is a new study drug intended to treat patients with cancer. The purpose of this study is to allow patients who are already taking dabrafenib to continue being treated with dabrafenib. The researchers hope to continue learning about the safety of dabrafenib (what effects, good or bad) in patients with BRAF mutation-positive tumors.
        Contact
        (210) 450-1912
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436...
        Protocol No.
        HSC20130060H
        Official Title
        A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects with V600 BRAF Mutation-Positive Tumors: An Open-Label, Dose-Escalating Safety Lead-In Study Followed by a Single-Sequence, Placebo-Controll
        Description
        A research study of Dabrafenib, which is a new study drug intended to treat patients with cancer. The researchers hope to learn the safety of dabrafenib (what effects, good or bad) and to determine if there are any effects of dabrafenib on the electrical activity of the heart. We are doing this study in patients with BRAF mutation-positive tumors.
        Contact
        210-450-1785
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   COG Diagnosis Registry
        Protocol No.
        HSC20040048H
        Official Title
        COG Diagnosis Registry
        Description
        The Registry of Newly Diagnosed Malignancies in Children and Adolescents is a diagnostic registry of all cancer cases in North America. This registry is referred to as the COG (Children''s Oncology Group) Diagnosis Registry.
        Contact
        210-567-7482
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Crizotinib in cancer patients with liver function impairment
        Protocol No.
        HSC20120328H
        Official Title
        A Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Crizotinib in Advanced Cancer Patients (CTRC#12-0059 )
        Description
        This Phase I study is designed to evaluate the potential effect of hepatic impairment on the pharmacokinetic profile and safety of crizotinib in advanced cancer patients. The primary objective is to compare the amount of drug in the blood between the different groups of patients with various degrees of liver function. The study will enroll approximately 50 from at least 4 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced cancer with mild, moderate or severe liver dysfunction as well as patients with normal liver function. Patients who have a history of uncontrolled ascites, prior treatment with crizotinib, spinal cord compression, congestive heart failure, severe lung disease, infection, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-1912
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Dose Escalating Study of AV-203 for Patients with Metastatic or Advanced...
        Protocol No.
        HSC20120161H
        Official Title
        A Phase 1/1b Open-Label, Dose Escalation Study of Monoclonal Antibody AV-203 Administered as Monotherapy in Subject with Metastatic or Advanced Solid Tumors or in Combination with Cetuximab (ErbituxTM) in Subjects with Recurrent or Metastatic Squamous Cel
        Description
        This purpose of this study is to determine the best dose of AV-203 to use when treating people with cancer that has spread to other areas in the body and/or cannot be removed surgically. The primary objective is to identify the side effects of AV-203 and to find out if AV-203 works as a treatment for cancer patients. The study will enroll at least 18 but not more than 96 participants from no more than 5 cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those whose tumors have become worse in spite of treatment and who are otherwise in good health. Because AV-203 is a monoclonal antibody and not a chemotherapy drug, patients’ tumors will be tested for the presence or absence of a specific protein that is involved in cancer growth.  Adult patients who have a history of cancer involving the central nervous system (brain), signs of an active infection including hepatitis, or heart disease may not be eligible to enroll.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Dose Escalating Study of IMGN853 for Patients with Cancer
        Protocol No.
        HSC20120333H
        Official Title
        A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1- Positive Solid Tumors (CTRC# 12-0064)
        Description
        The purpose of this study is to determine the best dose of IMGN853 to use when treating people with cancer, in particular, ovarian cancer, that has spread to other areas in the body and/or cannot be removed surgically. The primary objective is to identify the side effects and right dose of IMGN853 and to find out if IMGN853 works as a treatment for patients with specific types of cancer. The study will enroll approximately 64 participants from no more than 6 cancer centers in the US. In addition to other conditions for enrollment, eligible adult patients are those whose tumors have become worse in spite of treatment and who otherwise are in good health.  The tumors of all potential participants will be tested for the presence of a specific protein and results of the test will help determine if the patient is a candidate for treatment with IMGN853. Likely tumors are those that began in the ovary or fallopian tube, but some types of lung cancer and kidney cancer might also have this protein present. Participants cannot have a history of bone marrow transplant, cornea (eye) problems, active infection, significant heart history, multiple sclerosis or nerve damage.
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Genetic Epidemiology of Breast and Ovarian Cancers
        Protocol No.
        HSC20070698H
        Official Title
        Genetic Epidemiology of Breast and Ovarian Cancers
        Description
        A research study about factors that might increase the chance of getting breast and ovarian cancers. Eligible: female 18-80 yr old; diagnosed with breast cancer under age 50; diagnosed with ovarian cancer at any age; strong family history of breast and/or ovarian cancer.
        Contact
        210-562-9123
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
        Protocol No.
        HSC20080462H
        Official Title
        Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination with the HDAC Inhibitor SAHA for the Treatment of Patients with Advanced Solid Tumors with an expansion study in advanced Renal and Colorectal Cancer (CTRC# 08-52)
        Description
        This study is designed to evaluate   hydroxychloroquine (HCQ) with vorinostat the safety and antitumor activity of   this drug combination in advanced cancer patients. The primary objective is to determine   the best dose and evaluate the safety and effectiveness of this drug   combination. The study will enroll   approximately 48 from one cancer center in San Antonio. In addition to other conditions   for enrollment, eligible patients have cancer that has not improved or has   come back after prior treatment but are otherwise in good health. After identifying   the best dose is identified, only patients with advanced renal cell cancer   and colorectal cancer will be enrolled. Patients who have a history of prior   treatment with vorinostat, hepatitis or active infections, inability to take   oral medication, gastrointestinal disorder that affects complete digestion or   other severe medical conditions may not be eligible to enroll.  
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   MRX34 as treatment for patients with unresectable liver cancer or metastatic...
        Protocol No.
        HSC20130176H
        Official Title
        A Phase 1, Multicenter Study of MRX34 Given Intravenously Two Times per Week for Three Weeks, Repeated Every Four Weeks in Patients with Unresectable Primary Liver Cancer or Advanced Metastatic Cancer With Liver Involvement (CTRC# 12-0110)
        Description
        This Phase I study is designed to evaluate the safety of MRX34 in patients with primary liver cancer or those with liver metastasis from other cancers. The primary objective is to identify the side effects of MRX34. The study will enroll approximately 48 patients at two cancer centers in Texas. In addition to other conditions for enrollment, eligible patients have liver cancer or advanced metastatic cancer with liver metastasis that cannot be removed surgically and are otherwise in good health. Patients who have a history of infection including hepatitis, bleeding problems, central nervous system involvement, or require anticoagulant therapy may not be eligible to enroll.
        Contact
        (210) 450-5964
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase 1 Study of Carfilzomib in Patients with Advanced Cancers and Various...
        Protocol No.
        HSC20130446H
        Official Title
        An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects with Advanced Malignancies and Varying Degrees of Hepatic Impairment (CTRC#13-0043)
        Description
        The purpose of this study is to compare the safety and effectiveness of carfilzomib, a drug that has not been FDA approved and is still in investigational status. The objective is to measure the amount of the drug in the blood at specific times following dosing. This study is being done in people with varying degrees of liver function to see if they respond differently to the study drug. The study will enroll approximately 40 from at least 3 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced cancer, either solid tumor or hematologic malignancy as well as chronic liver impairment that has been stable with no sudden worsening within one month prior to enrollment. Patients who have a history of inadequate kidney function, congestive heart failure or other serious heart condition, brain metastasis, chronic infection, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-5816
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase I Dose Escalating Study of Hydroxychloroquine plus Sorafenib for...
        Protocol No.
        HSC20120203H
        Official Title
        A Phase I Dose-Escalation Trial of Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients with Refractory or Relapsed Solid Tumors (CTRC# 11-71)
        Description
        The purpose of this study is to determine the best dose of hydroxychloroquine to use when combined with sorafenib to treat people with cancer that has spread to other areas in the body and/or cannot be removed surgically. The primary objective is to identify the side effects of hydroxychloroquine plus sorafenib and to find out if hydroxychloroquine plus sorafenib works as a treatment for cancer patients. The study will enroll a maximum of 24 participants at the CTRC in San Antonio. In addition to other conditions for enrollment, eligible patients are those whose tumors have become worse in spite of treatment and who are otherwise in good health.  Eligible patients are not taking digoxin (Lanoxin®) or cimetidine (Tagamet®) nor have they been treated previously with sorafenib (Nexavar®).  Patients with heart problems or uncontrolled high blood pressure may not be eligible.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase I Dose Escalating Study of XRP6258 for Patients with Cancer and...
        Protocol No.
        HSC20100304H
        Official Title
        NULL
        Description
        The purpose of this study is to determine the best dose of XRP6258 to use when treating people with a liver that does not work well and cancer that has spread to other areas in the body and/or cannot be removed surgically. The primary objective is to compare the effects of mild or moderate liver dysfunction to normal liver function in the way that XRP6258 (Cabazitaxel) is metabolized (or broken down and passed from the body) in patients with advanced solid tumors. The study will enroll approximately 39 to 75 participants from approximately 15 cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those whose tumors have become worse in spite of treatment and who are otherwise in good health.  Patients who have a history of bone marrow transplant, Gilbert’s syndrome, or cancer involving the central nervous system (brain) may not be eligible to enroll.
        Contact
        (210) 450-5816
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase I Study of BAX69 for Patients with Solid Tumors
        Protocol No.
        HSC20120141H
        Official Title
        A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects with Malignant Solid Tumors (CTRC# 12-03)
        Description
        The purpose of this study is to determine the best dose of BAX69 to use when treating people with cancer that has spread to other areas in the body and/or cannot be removed surgically. The primary objective is to identify the side effects of BAX69 and to find out if BAX69 works as a treatment for cancer patients. The study will enroll approximately 32 to 44 participants from a several cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those whose tumors have become worse in spite of treatment and who are otherwise in good health.  Adult patients who have a history of cancer involving the central nervous system (brain), recent heart problems, uncontrolled blood pressure problems, recent major surgery, inflammatory arthritis, or hepatitis may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of...
        Protocol No.
        HSC20130180H
        Official Title
        A Phase Ib, Multi-Center, Two Parallel Group, Open-Label, Drug-Drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients with Advanced Solid Tumors (CTRC# 12-0111)
        Description
        This Phase I study is designed to evaluate a possible drug-drug interaction between LDE225 on warfarin and bupropion in patients with advanced cancer.   The primary objective is to determine if LDE225 has a drug interaction with bupropion and warfarin.    The study will enroll approximately 60 patients at several cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced cancer that has become worse in spite of therapy and are otherwise in good health. Patients who have a history of brain metastases, bleeding disorders, neuromuscular disorders, infection including hepatitis, or are already on bupropion (Wellbutrin), warfarin (Coumadin), or vitamin K therapy may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase Ib study of BGJ398 in combination with BYL719 in patients with...
        Protocol No.
        HSC20140022H
        Official Title
        A phase Ib, open-label study of oral BGJ398 in combination with oral BYL719 in adult patients with select advanced solid tumors
        Description
        This Phase 1 study is designed to evaluate the combination of BGJ398 and BYL719. in patients with cancers that have a specific genetic mutation. The objective of the study is to determine the safety and effectiveness of the combination of BGJ398 and BYL719. The primary objective of the study is to evaluate the safety and effectiveness of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA In addition to other conditions for enrollment, eligible patients have cancer that has not improved or has come back after prior treatment and are otherwise in good health. Patients with diabetes mellitus, particularly those requiring treatment with insulin, may not be eligible. The study will enroll approximately 55 patients from at least 27 cancer centers in the US, Europe, and Asia.
        Contact
        (210) 450-5595
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Prognostic and predictive markers in patients with advanced metastatic tumors
        Protocol No.
        HSC20130219H
        Official Title
        Numeration and Single-Cell Molecular Profiling of Circulating Tumor Cells as Prognostic and Predictive Marker In Patients with Advanced Metastatic Tumors (CTRC#13-0001)
        Description
        This study will research possible associations between circulating tumor cells (CTC) quantities or gene profile characteristics and clinical outcomes. The primary objective is to obtain blood samples from participants over an 8-week period for research analysis.  The study will enroll approximately 200 patients at the CTRC. In addition to other conditions for enrollment, eligible patients have advanced metastatic cancer.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   SCUSF 1202 [prev. ACCL1032], A Randomized Controlled Trial of Acupressure to...
        Protocol No.
        HSC20130271H
        Official Title
        SCUSF1202 [prev. ACCL1032], A Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea in Children Receiving Highly Emetogenic Chemotherapy (previously ACCL1032)
        Description
        To treat people for nausea and vomiting, which can happen with cancer treatment, people often get another medicine as standard treatment. This other medicine is usually either ondansetron or granisetron. But often, people still have nausea and vomiting. This study looks at how well adding a treatment called acupressure to the standard treatment works for treating the nausea and vomiting that can come with chemotherapy. Acupressure uses elastic wrist bands worn during and after chemotherapy.
        Contact
        210-567-7482
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Timolol For The Prevention Of Proliferation Of Infantile Hemangioma (TiPPIH...
        Protocol No.
        HSC20110333H
        Official Title
        Timolol For The Prevention Of Proliferation Of Infantile Hemangioma (TiPPIH Trial)
        Description
        A research study of a new treatment for infantile hemangiomas. Hemangiomas are one of the most common childhood benign (non-cancerous) vascular tumors.
        Contact
        210-724-2744
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Non-Hodgkin's Lymphoma

      •   An Open Label, Phase 1, Two-Way Cross-Over Study of the Effect of the Food...
        Protocol No.
        HSC20130285H
        Official Title
        An Open Label, Phase 1, Two-Way Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients with Advanced Solid Tumors or Lymphomas (CTRC# 12-0102)
        Description
        A research study of alisertib in advanced solid tumors or lymphomas. The researchers hope to learn the effect on the pharmacokinetics (the amount of drug in the body over time) when taken the drug on an empty stomach (fasted) and after eating a high-fat breakfast (fed).
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   IMGN529 as Treatment for Patients with Advanced Non-Hodgkin''s Lymphoma
        Protocol No.
        HSC20130331H
        Official Title
        A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients with Relapsed or Refractory Non-Hodgkin''s Lymphoma (CTRC#13-0025)
        Description
        This Phase 1 study is designed to evaluate the safety and tolerability of IMGN529 when used to treat patients with relapsed or refractory non-Hodgkin''s lymphoma (NHL). The study will enroll approximately 46 patients from at least 5 cancer centers in the US and Switzerland. In addition to other conditions for enrollment, eligible patients have relapsed or refractory non-Hodgkin''s lymphoma that has not improved or has come back after prior treatment and are otherwise in good health. Patients who have a history of allogeneic stem cell transplantation or known lymphoma involving the central nervous system, including brain metastases, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Ofatumumab plus bendamustine as Treatment for Indolent B-cell Non-Hodgkin''s...
        Protocol No.
        HSC20120240H
        Official Title
        An Open-Label Phase I Drug-Drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects with Indolent B-cell Non-Hodgkin''s Lymphoma (CTRC#12-0045)
        Description
        This is a Phase I drug-drug interaction study of ofatumumab with bendamustine.  The primary objective is to identify the safety, tolerability, and efficacy of ofatumumab and bendamustine. The study will enroll approximately 30 patients from several cancer centers in the US. In addition to other conditions for enrollment, eligible patients have previously untreated or relapsed indolent B-cell non-Hodgkin''s lymphoma (NHL) and are otherwise in good health. Adult patients who have a history of stem cell transplant, an aggressive form of lymphoma, active infection including hepatitis B or C, significant cardiac or cerebrovascular disease, active liver or gall bladder disease may not be eligible to enroll. Patients who have been previously treated with ofatumumab or bendamustine are not eligible to enroll.
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Other female genital

      •   Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating...
        Protocol No.
        HSC20130196H
        Official Title
        RTOG 1203 A Randomized Phase III Study of Standard vs IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) (CTRC#13-0004)
        Description
        This Phase III study evaluates two different methods of radiation, comparing the side effects and the effectiveness, when used as treatment for endometrial and cervical cancer after surgery. The primary objective is to evaluate and compare the acute gastrointestinal side effects of IMRT vs standard radiotherapy. The study will enroll approximately 281 patients many cancer centers in the US. In addition to other conditions for enrollment, eligible patients have endometrial or cervical cancer, have undergone a hysterectomy, and are otherwise in good health. Patients who have a history of bladder control problems, prior radiation to the pelvis, active inflammatory bowel disease, cardiac history, infection, prior treatment with platinum-based chemotherapy, or insufficient liver function may not be eligible to enroll.
        Contact
        210-450-5924
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Other Hematopoietic

      •   AVL-292 as Treatment for Patients with Non-Hodgkin Lymphoma, Chronic...
        Protocol No.
        HSC20110412H
        Official Title
        NULL
        Description
        This is a Phase I dose escalation clinical trial for patients with B-NHL, CLL, or WM who have failed at least 1 prior therapy. The primary objective is to identify the side effects of AVL-292 when administered orally once a day or twice a day as treatment for patients with relapsed or refractory B cell non-Hodgkin’s lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), or Waldenström’s macroglobulinemia (WM). The study will enroll up to 72 patients (24 of each diagnosis) from many cancer centers in the US. Study enrollment may expand to enroll up to a total of 240 patients. In addition to other conditions for enrollment, eligible patients are those whose cancer has become worse in spite of treatment and who are otherwise in good health. Eligible patients are able to swallow oral medication without difficulty. Adult patients who have a history of bone marrow transplant, central nervous system involvement by lymphoma, heart attack or other cardiac complications, active infection including hepatitis B or C, or a malabsorption problem may not be eligible to enroll.
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   GA101 (RO5072759, obinutuzumab) in Combination with CHOP Chemotherapy as...
        Protocol No.
        HSC20110397H
        Official Title
        A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients with Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated with GA101 (RO5072759) in Combination with CHOP Chemotherapy (IDD# 11-20)
        Description
        This is a Phase II clinical trial using GA101 in addition to CHOP chemotherapy as treatment for previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL). The primary objective is to determine the effectiveness of adding GA101 to CHOP chemotherapy as treatment for diffuse large B-cell lymphoma. The study will enroll up to 95 patients from x cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those who have not been treated with chemotherapy for their lymphoma and who are otherwise in good health. Adult patients who have a history of uncontrolled or significant cardiovascular diagnosis or active infection including hepatitis B may not be eligible to enroll.
        Contact
        (210) 450-5021
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients...
        Protocol No.
        HSC20130307H
        Official Title
        Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients with Advanced B-cell Hematologic Malignancies (CTRC#13-0013)
        Description
        This Phase 0/1 study is designed to determine if roflumilast improves how prednisone works when used to treat patients with B-cell hematologic malignancies. The primary objective is to evaluate the safety of administering roflumilast with prednisone. The study will enroll approximately 10 patients from the CTRC in San Antonio. In addition to other conditions for enrollment, eligible patients have relapsed or refractory B-cell hematologic malignancy that has failed at least 1 prior treatment, and are able to swallow oral medications. Patients who have a history of recent bone marrow or stem cell transplant, inadequate blood counts, an active infection, serious cardiac abnormalities, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-1804
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Serum Markers of Angiogenesis in patients with Von Hippel-Lindau Disease
        Protocol No.
        HSC20090283H
        Official Title
        Serum Markers of Angiogenesis in patients with Von Hippel-Lindau Disease
        Description
        This research which will study blood samples and compare it to other people from families with Von-Hippel Lindau (VHL) disease. VHL disease is caused by an abnormal growth of blood vessels which can lead to tumors or cancer. We are looking for elements in the blood that might cause such abnormal blood vessel growth. The researchers hope to learn more about the cancers involved in Von Hippel-Lindau (VHL) disease.
        Contact
        210-562-9123
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Pancreas

      •   M402 plus gemcitabine compared to gemcitabine alone as treatment for...
        Protocol No.
        HSC20120151H
        Official Title
        A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer (CTRC# 12-11)
        Description
        This is a Phase I/II study comparing gemcitabine alone to gemcitabine plus M402 as treatment for metastatic pancreatic cancer.  The primary objective is to compare overall survival in patients treated with M402 in combination with gemcitabine compared with gemcitabine alone. The study will enroll approximately 138 patients from 6 cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those whose pancreatic cancer has become spread but has not been treated with chemotherapy and who are otherwise in good health. Adult patients who have a history of treatment with gemcitabine, blood clotting disorders, needing anti-platelet therapy, coronary artery disease, active infection including hepatitis B or C may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Prostate

      •    Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test.
        Protocol No.
        HSC20100352H
        Official Title
        Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test
        Description
        Eligibility Criteria: Men at risk of prostate cancer who are considering a prostate biopsy with an elevated PSA.
        Contact
        210-567-1995
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Canary Prostate Active Surveillance Study (PASS)
        Protocol No.
        HSC20080303H
        Official Title
        Canary Prostate Active Surveillance Study (PASS)
        Description
        All care participants receive is Standard of Care for Active Surveillance. Research procedures include blood draw every 6 months for serum and plasma, urine collections, prostate tissue collection, Food & Supplement Use Questionnaire and the Health-Related Quality of Life Questionnaire. Purpose of the PASS is to understand how prostate cancer behaves and to find unique biomarkers (substances in blood, urine or tissue which can indicate the presence of cancer) associated with prostate cancer. Eligibility Criteria: Participant must have clinically localized prostate cancer that has not been treated. Participant has elected active surveillance and decided not to undergo surgery, radiation, or other medical treatment for prostate cancer at this time.
        Contact
        210-450-0705
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Castration Compared to Castration Plus Metformin as First Treatment for...
        Protocol No.
        HSC20110273H
        Official Title
        Phase II, Randomized,Placebo Controlled, Double Blind, Prospective Study of Castration Compared to Castration Plus Metformin as First Line Treatment for Patients with Advanced Prostate Cancer (IDD# 10-21)
        Description
        This is a Phase II double blind study comparing castration alone vs castration plus metformin. Double blind means neither the patient nor the doctor know whether the study participant is getting metformin or the placebo.  The primary objective is to determine if adding metformin to castration is better or different compared to castration alone. The study will enroll 94 patients at the CTRC. In addition to other conditions for enrollment, eligible patients have metastatic prostate cancer that require castration therapy by using either an LHRH analogue or surgical castration and are otherwise in good health. Men who have a history of inadequate heart, kidney, or liver function, serious infections, alcohol abuse, or lactic/metabolic acidosis may not be eligible to enroll.
        Contact
        (210) 450-5964
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   ECOG E3805 - CHAARTED: ChemoHormonal Therapy versus Androgen Ablation...
        Protocol No.
        HSC20090050H
        Official Title
        ECOG E3805 - CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer
        Description
        This study is being done to find out how adding chemotherapy to hormonal therapy affects the quality and length of life in patients with advanced prostate cancer. The researchers hope to learn whether receiving docetaxel both when start hormone therapy (or within 120 days of beginning hormonal therapy) as well as when disease worsens, is better than only receiving docetaxel when disease gets worse. This trial will let us know which approach is more effective in treating the disease. The US Food and Drug Administration (FDA) considers the use of docetaxel to be investigational (experimental for treating advanced prostate cancer).
        Contact
        210-450-1233
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Hormonal Therapy plus Radiation Therapy as Treatment for Prostate Cancer
        Protocol No.
        HSC20130062H
        Official Title
        RTOG 0924 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
        Description
        The purpose of this study is determine which type of anti-hormonal therapy and radiation therapy will result in an improvement in survival in patients with “unfavorable” intermediate risk or “favorable” high risk prostate cancer.  The risk is the possibility or chances of the prostate cancer coming back after being treated. The primary objective is to see which treatment improves the duration of survival. The study will enroll 2,580 participants from many cancer centers in the US. In addition to other conditions for enrollment, men who were diagnosed with prostate cancer within the past 180 days and have no evidence of lymph node involvement by CT scan or MRI within the past 90 days may be enrolled. Men are not eligible for this study if the prostate or testes have been surgically removed. Men who have already been treated with brachytherapy or radiation to the pelvis or hormonal therapy are not enrolled. Patients with a history of other cancers may not be eligible.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk...
        Protocol No.
        HSC20020380H
        Official Title
        Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease
        Description
        The purpose of this study is to identify genetic variants that predict progression of prostate cancer.
        Contact
        210-567-0214
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Soft Tissue

      •   Assessing Change in Chromosomal Abnormalities of Ocular Melanoma Over Time
        Protocol No.
        HSC20090453H
        Official Title
        Assessing Change in Chromosomal Abnormalities of Ocular Melanoma Over Time
        Description
        A research study of cell changes that occur in ocular melanoma tissue over time. Ocular melanoma is a specific type of eye cancer. Melanoma tissue samples are taken from eyes that are surgically removed for diagnosis and treatment.
        Contact
        210-450-0636
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Patients with...
        Protocol No.
        HSC20120153H
        Official Title
        A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma (CTRC# 12-10
        Description
        This is a Phase 2b randomized, multicenter study comparing treatment with INNO 206 to doxorubicin in patients with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy.  The primary objective is to identify the effect of treatment on preventing disease progression. The study will enroll 105 patients from 36 cancer centers US, Europe, and Asia. In addition to other conditions for enrollment, eligible patients are 15 to 80 years old and who are otherwise in good health. Patients who have a history of central nervous system (brain) metastasis, significant cardiac events, or active infection may not be eligible to enroll.
        Contact
        (210) 450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   YONDELIS® (trabectedin) as Treatment for Locally Advanced or Metastatic...
        Protocol No.
        HSC20130148H
        Official Title
        A Multicenter, Open-Label Single-Arm Study of YONDELIS® (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment (CTRC#12-0107)
        Description
        The purpose of this study is to facilitate access to trabectedin for eligible, previously treated patients with soft tissue sarcoma, excluding liposarcoma and leiomyosarcoma (L-type sarcoma), who cannot be expected to benefit from currently available therapeutic options but who may benefit from treatment with trabectedin. The safety profile of trabectedin will be evaluated to further assess the potential risks of trabectedin treatment. The study will enroll approximately 3,000 patients from at least 36 cancer centers in the US, Canada, and Israel. In addition to other conditions for enrollment, eligible patients are at least 15 years old, have soft tissue sarcoma excluding liposarcoma and leiomyosarcoma (L-type soft tissue sarcoma) that cannot be surgically removed and is in an advanced stage or has spread. Patients who have symptomatic viral hepatitis or chronic liver disease, a significant uncontrolled cardiac condition, active infection, or other severe medical conditions may not be eligible to enroll.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Urinary Bladder

      •    Surveillance for low and low-intermediate-risk non-muscle invasive bladder...
        Protocol No.
        HSC20130177H
        Official Title
        Surveillance for low and low-intermediate-risk non-muscle invasive bladder cancer: A Pilot Study (CTRC#12-0108)
        Description
        A research study of 2 different approaches taken to monitoring patients with bladder cancer. In the United States, we generally follow patients by looking into their bladder every 3 months for the first year following diagnosis. On the other hand, in Europe, a less frequent approach is used (once at 3 months and again at 12 months). We believe that these approaches would not have any untoward consequences for patients, such as disease progression, but this has not been proven. This is a pilot study that aims to compare these 2 different strategies for monitoring patients with bladder cancer. We are capturing information about patient satisfaction and cost and differences in cancer relapse rates.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   DN24-02 as Adjuvant Therapy for patients with high risk HER2-positive...
        Protocol No.
        HSC20130157H
        Official Title
        A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma (CTRC# 12-0084)
        Description
        This Phase II study evaluates the safety, survival, and the magnitude of the induced immune response following the administration of DN24-02 in patients with HER2-positive urothelial carcinoma (e.g., bladder, urethra, ureter, kidney cancer). The primary objective is to determine whether taking DN24-02 helps patients to live longer compared to standard of care. The study will enroll approximately 180 patients from more than 50 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have no evidence of residual or metastatic disease, are less than 12 weeks from surgery to remove the cancer, and are otherwise in good health. Patients who have a history of partial resection or prior adjuvant therapy may not be eligible to enroll.
        Contact
        (210) 450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy
        Protocol No.
        HSC20120135H
        Official Title
        NULL
        Description
        This study will evaluate the effects of rapamycin directly on bladder tumors and the effects of rapamycin on the immune system of patients with bladder cancer. The purpose of this pre-surgical, clinical trial is to understand the biologic activity of rapamycin and its safety in patients with bladder cancer.   Eligible patients have invasive bladder cancer and are candidates for bladder removal surgery.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Standard or Extended Pelvic Lymph Node Surgery as Part of Treatment for...
        Protocol No.
        HSC20110462H
        Official Title
        S1011: A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer (IDD# 11-46)
        Description
        This purpose of this study is to determine whether standard surgery to remove the pelvic lymph nodes works the same, better, or worse than extended pelvic lymph node removal when treating patients with surgery for invasive bladder cancer. The primary objective is to compare the difference, if there is any, in the length of time it takes bladder cancer to come back and/or spread to other parts of the body in patients who have been diagnosed with muscle-invasive bladder cancer who are undergoing surgery to remove the entire bladder.  Study participants will have either extended pelvic lymph node removal or standard pelvic lymph node removal. The study will enroll 620 participants from many cancer centers in the US. In addition to other conditions for enrollment, patients have urothelial cancer of the bladder and require surgery for definitive treatment.  Eligible patients have not had prior surgery to remove part of the bladder or any pelvic lymph node s. Eligible patients have not had prior pelvic radiation therapy.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        Learn More About This Study

         

  •   Diagnostic

    •   New Cancer Diagnosis Costs and Follow up Patterns for Uninsured vs Insured...
      Protocol No.
      HSC20140018H
      Official Title
      New Cancer Diagnosis Costs and Follow up Patterns for Uninsured vs Insured Patients: A Quality Improvement Project (CTRC#13-0038)
      Description
      This is a quality improvement project with the primary objective of examining the current cost of caring for newly diagnosed cancer patients at University Hospital. We will estimate the cost of each admission by looking specifically at length of inpatient stays as well as procedures performed and their associated costs. We plan to compare these costs between uninsured patients versus patients with medical insurance, as well as compare the costs between various cancer types.
      Contact
      210-450-5798
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Genetics

    •   Development of potential response to radiation phenotypes (RRPs) for genetic...
      Protocol No.
      HSC20130198H
      Official Title
      Development of potential response to radiation phenotypes (RRPs) for genetic studies: a pilot study
      Description
      Although cancer treatment with radiation can produce high cure rates, adverse effects often result from radiotherapy. Therefore, the major objective of this pilot project is to develop potential response to radiation phenotypes (RRPs) and to explore their genetic basis.
      Contact
      210-258-9532
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genetic Epidemiology of Lung Cancer: Genetic markers associated with gender,...
      Protocol No.
      HSC20090349H
      Official Title
      Genetic Epidemiology of Lung Cancer: Genetic markers associated with gender, age and smoking history
      Description
      Although smoking is a known contributing risk factor for developing lung cancer we believe other factors may also be associated with this condition. The incidence of lung cancer in women has continued to rise over the past several decades despite a declining incidence in men. The increase in lung cancer in women has been, in part, explained by an increase in smoking in women, however, we believe certain hormonal factors, along with specific genetic factors may influence the development of lung cancer. The researchers are interested in finding better ways to detect lung cancer, to treat it, and, if possible, to prevent the occurrence of lung cancer. More information is needed in order to determine what causes lung cancer and how lung cancer is related to heredity. Lung cancer may result from genetic factors - things passed on to us from our ancestors that we, in turn, pass onto our children.
      Contact
      210-562-9123
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Men's Health

    •   Biomarkers and Clinical Data Associated with upgrading from low-grade...
      Protocol No.
      HSC20140367H
      Official Title
      Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading
      Description
      This study is for men who have already been diagnosed with prostate cancer and have elected radical prostatectomy (removal of the prostate) as treatment. The study is on why less aggressive prostate cancer may sometimes develop into more aggressive prostate cancer and will enroll approximately 600 study participants, across all sites. Participants will undergo procedures prior to the surgery with possible long-term follow up participation lasting up to 10 years. Participants will be asked to sign a medical release form so we can request prostate biopsy pathology reports and biopsy slides and blocks in order to confirm a prostate cancer diagnosis. Participants will be asked to complete forms and questionnaires providing information regarding medical history, risk factors such as alcohol and smoking, race and ethnicity, and family history of prostate cancer. Following the medical history, trained research staff will draw blood samples for research purposes. Participants will be asked to complete a digital rectal exam prior to the surgery and provide a urine sample that will be tested for potential biomarkers associated with prostate cancer. We will request that blood, urine, and prostate tissue samples be stored in our central research repository. Materials collected in the repository may be used for future research associated with prostate cancer. Participants may be contacted for follow up information to determine disease progression, if any. Participants can withdraw from the study anytime.
      Contact
      210-567-0178
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Salivary biomarker to measure fatigue in prostate cancer patients
      Protocol No.
      HSC20130013H
      Official Title
      Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue, Quality of Life and Physical Function in Prostate Cancer Survivors
      Description
      The purpose of this study is to test the application of a new biomarker to measure fatigue from saliva. Men with and without prostate cancer are being recruited for this study. The research study consists of a single visit at which time a saliva sample will be collected and surveys will be completed.
      Contact
      210-567-0362
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Minority Studies

    •   Persistent tanning as a novel adaptation to ultraviolet radiation in...
      Protocol No.
      HSC20130334H
      Official Title
      Persistent tanning as a novel adaptation to ultraviolet radiation in Indigenous Americans
      Description
      A study of tanning response in Mexican American individuals. We want to learn whether an individual''s ability to tan and the length of time that tan persists is related to Native American ancestry and specific genes. We are testing the hypothesis that increased tanning may have evolved in Native Americans to adapt to intense ultraviolet radiation (UVR) in tropical and subtropical regions. We are interested in tanning response because it is a risk factor for skin cancer and vitamin D deficiency, a risk factor for a number of diseases.
      Contact
      210-258-9470
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Nutrition

    •   Prevention of Hepatocellular Carcinoma in Vulnerable Communities in Texas
      Protocol No.
      HSC20120215H
      Official Title
      Prevention of Hepatocellular Carcinoma in Vulnerable Communities in Texas
      Description
      The primary purpose of the study is to evaluate the effectiveness of a naturally occurring clay substance (ACCS100) in reducing harmful effects of aflatoxin (a carcinogen) and fumonisin (a cancer promoter) exposure. This clay substance contains of a variety of minerals including calcium, sodium, potassium, and magnesium. UPSN and similar aluminosilicate minerals have been regularly used as dietary supplements by humans and animals, and the safety of this naturally occurring clay substance has been tested in clinical trials. The FDA treats such minerals or nutritional supplements as a drug when tested for potential of lessening the likelihood of disease (i.e., potential for mitigating disease). This study involves the use of an investigational drug called Hydrated Sodium Calcium Aluminosilicate (ACCS100). "Investigational" means that the "drug" has not yet been approved by the U.S. Food & Drug Administration (FDA) for reducing harmful effects of mycotoxin exposure in humans.
      Contact
      210-567-0846
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Other

    •   Open Vs. Robotic-Assisted Radical Cystectomy: A Randomized Trial
      Protocol No.
      HSC20090150H
      Official Title
      Open Vs. Robotic-Assisted Radical Cystectomy: A Randomized Trial
      Description
      Eligibility Criteria:Patient must have biopsy-proven bladder cancer; official pathology report reviewed by PI is required; bladder cancer must be clinical state T1-T4, N0-1, M0 (AJC 7th Edition) or refractory carcinoma in situ (cis).
      Contact
      210-450-0752
      Locations
      UT Health Science Center
      Learn More About This Study